Peri-neural Dexmedetomidine Versus Dexamethasone for Supraaclavicular Block Adjuvant to Bupivacaine Supraclavicular Brachial Plexus Block

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-01

Study Completion Date

2020-01-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

to assessthe impact of addition of Dexmedetomidine or Dexamethasone to Bupivacaine, on Duration of analgesia (time in hours to the first report of postoperative pain )at the surgical site

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Different Medications as Adjuvants in Ultrasound-guided Supraclavicular Brachial Plexus Block in Forearm Surgeries

NCT06949488

Upper Limb Surgery Brachial Plexus Blockade

ACTIVE_NOT_RECRUITING NA

Perineural Dexmedetomidine and Femoral Nerve Block

NCT01964040

Onset and Duration of Sensory and Motor Block of Femoral Nerve, Visual Analogue Pain Scores, Time to First Request of Rescue Analgesics, +1 more

UNKNOWN PHASE4

Dexamethasone Dose in Low Volume Bupivacaine USG Supraclavicular Block

NCT03043495

Dexamethasone Supraclavicular Brachial Plexus Block

UNKNOWN PHASE4

Infraclavicular Brachial Plexus Block With Bupivacaine Alone or With Both Dexmedetomidine and Dexamethasone

NCT06356415

Upper Extremity Injury

NOT_YET_RECRUITING NA

Ultrasound Guided Infraclavicular Brachial Plexus Block Using Levo-bupivacaine Alone or Combined With Dexmedetomidine for Hand and Forearm Surgeries

NCT04729868

Acquired Deformity of Elbow Forearm Hand +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This randomized, controlled double blinded study included 42 adult patients undergoing arteriovenous fistula surgery. Ultrasound-guided supraclavicular brachial plexus block was initiated after placement of full monitoring . Supraclavicular brachial plexus block was achieved with the use of total volume 32 ml of anesthetic drugs in all patients. Bupivacaine 30 ml 0.25% was combined with 2 ml normal saline (control group A, n=14), Bupivacaine 30 ml 0.25% was combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline ( dexmedetomidine group B ,n=14), or Bupivacaine 30 ml 0.25% was combined with 4 mg peri neural dexamethasone (2 ml) ( dexamethasone group C, n=14).The onset and duration of sensory and motor blocks, the time to first request to postoperative rescue analgesic, Richmond Agitation-Sedation Score, hemodynamic data, visual analogue pain scores, were reported at predetermined time assessment points. Postoperative rescue intravenous fentanyl consumption over 24 hours and complications occurred were recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brachial Plexus Block

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel Assignment

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Caregivers

double blind both anesthetist and patient not aware about type of local anesthesia

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dexmedetomidine

Bupivacaine 30 ml 0.25% was combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline

Group Type ACTIVE_COMPARATOR

Dexmedetomidine injection

Intervention Type DRUG

perineural injection of Bupivacaine 30 ml 0.25% combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline

dexamethasone

Bupivacaine 30 ml 0.25% was combined with 4 mg peri neural dexamethasone (2 ml)

Group Type ACTIVE_COMPARATOR

Dexamethasone

Intervention Type DRUG

perineural injection of Bupivacaine 30 ml 0.25% combined with 4 mg peri neural dexamethasone (2 ml)

control group

Bupivacaine 30 ml 0.25% was combined with 2 ml normal saline

Group Type PLACEBO_COMPARATOR

saline

Intervention Type DRUG

perineural injection of Bupivacaine 30 ml 0.25% combined with 2 ml normal saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine injection

perineural injection of Bupivacaine 30 ml 0.25% combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline

Intervention Type DRUG

Dexamethasone

perineural injection of Bupivacaine 30 ml 0.25% combined with 4 mg peri neural dexamethasone (2 ml)

Intervention Type DRUG

saline

perineural injection of Bupivacaine 30 ml 0.25% combined with 2 ml normal saline

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

precedex decadrone normal saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All the patients included in the study aged 18 to 60 years old were on chronic hemodialysis and they had a hemodialysis session one day before the block performance

Exclusion Criteria

* Neurological, neuromuscular, psychiatric disorders, hepatic, respiratory, or cardiac diseases; coagulation disorders; infection at the block injection site; patients with a body mass index more than 35; or patients who refused the procedure

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No